Why does Amgen present non-GAAP financial measures?

Amgen presents non-GAAP financial measures to provide investors with additional insights into the company's ongoing operational performance. By excluding items like acquisition-related expenses, restructuring costs, and legal settlements, the company aims to offer a clearer picture of its core business profitability and facilitate more meaningful comparisons with historical and future performance.

What specific costs are excluded from Amgen's non-GAAP results?

Amgen excludes acquisition-related expenses (primarily amortization of intangible assets from acquisitions), net charges related to restructuring initiatives, and certain legal judgments or settlements that are considered outside the ordinary course of business. The tax effects of these adjustments are also accounted for.

What is Free Cash Flow (FCF) and why is it important for investors?

Free Cash Flow (FCF) is calculated by subtracting capital expenditures from operating cash flow, as determined by GAAP. Amgen presents FCF as a measure of liquidity, providing investors with insight into the cash generated by the company's operations after accounting for investments in its assets. This metric can indicate the company's ability to fund operations, pay dividends, and reinvest in the business.

AMGN 8-K: Earnings & Results

Q: What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially furnish Amgen's press release detailing its unaudited financial results for the three and nine months ended September 30, 2019. It serves as a formal record of these results, which were released concurrently.

Summary

Amgen Inc. (AMGN) filed an 8-K on October 29, 2019, to report its unaudited financial results for the three and nine months ended September 30, 2019. The filing primarily serves to furnish a press release detailing these results, which includes both GAAP and non-GAAP financial measures. Investors should note that Amgen utilizes non-GAAP measures to provide a clearer view of its ongoing business performance by excluding certain items. These excluded items include acquisition-related expenses (such as amortization of acquired intangible assets), restructuring charges, and certain legal settlement costs. The company believes these adjustments facilitate a more meaningful comparison of operational performance across periods. Free Cash Flow (FCF) is also presented as a measure of liquidity. The press release, furnished as Exhibit 99.1, offers a more detailed breakdown of the financial performance. Investors are encouraged to review the full press release for the specific figures and the reconciliations between GAAP and non-GAAP measures. Amgen's management uses these non-GAAP measures to enhance understanding of the company's financial health and future prospects, focusing on core operational activities. This filing is crucial for investors seeking to understand the company's financial trajectory beyond standard accounting definitions.

Key Highlights

1Amgen reported unaudited financial results for the third quarter and first nine months of 2019.
2The company provided both GAAP and non-GAAP financial measures in its press release.
3Non-GAAP measures exclude acquisition-related expenses (amortization of intangibles), restructuring costs, and legal settlements to reflect core operating performance.
4Free Cash Flow (FCF) was presented as an additional liquidity metric.
5The press release, furnished as Exhibit 99.1, contains detailed financial data and reconciliations.
6Management uses non-GAAP measures to provide supplementary analysis and facilitate period-over-period comparisons of ongoing business operations.
7This filing is primarily informational, furnishing a press release rather than detailing new material events within the 8-K itself.

AMGEN INC 8-K Report, Financial Results (Oct 29, 2019)

Summary

Key Highlights

Frequently Asked Questions